Drug Trial Radar · NCT05478499
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Oct 6, 2022
Primary completion
Jan 11, 2024
Study completion Oct 17, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Conditions
- Psoriasis
Interventions
DeucravacitinibDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16Time frame: Baseline and Week 16
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
Local Institution - 0001
Hot Springs, Arkansas
Local Institution - 0007
Indianapolis, Indiana
Local Institution - 0041
Louisville, Kentucky
Local Institution - 0022
Rockville, Maryland
Local Institution - 0008
Beverly, Massachusetts
Local Institution - 0047
Bloomfield Hills, Michigan
Local Institution - 0002
New Brighton, Minnesota
Local Institution - 0049
East Windsor, New Jersey
Local Institution - 0051
Kew Gardens, New York
Local Institution - 0003
Portland, Oregon
Local Institution - 0005
Pittsburgh, Pennsylvania
Local Institution - 0033
Houston, Texas
Local Institution - 0004
San Antonio, Texas
Local Institution - 0006
Norfolk, Virginia
Local Institution - 0019
Paris, France
Local Institution - 0040
Romans-sur-Isère, France
Local Institution - 0044
Rouen, France
Local Institution - 0048
Hamburg, Germany
Local Institution - 0012
Lübeck, Germany
Local Institution - 0011
Mahlow, Germany
Local Institution - 0038
Witten, Deutschland, Germany
Local Institution - 0013
Frankfurt am Main, Hesse, Germany
Local Institution - 0026
Krakow, Poland
Local Institution - 0017
Lodz, Poland
Local Institution - 0014
Rzeszów, Poland
Local Institution - 0015
Wroclaw, Poland
Local Institution - 0031
London, Greater London, United Kingdom
Local Institution - 0045
Salford, Greater Manchester, United Kingdom
Local Institution - 0039
Southampton, HAMPSHIRE, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.